Your browser doesn't support javascript.
loading
Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study.
Shi, Bin; Zhang, Rong-Rong; Liang, Ying; Wang, Xin-Hui; Lang, Rui; Yu, Ren-Huan.
Afiliação
  • Shi B; Graduate School of Beijing University of Chinese Medicine, Beijing, China.
  • Zhang RR; China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Liang Y; China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Wang XH; China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Lang R; China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Yu RH; China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Article em En | MEDLINE | ID: mdl-30344612
BACKGROUND: The treatment of adult refractory idiopathic membranous nephropathy with steroid and other immunosuppressant-resistant nephrotic syndromes can be a significant challenge. We evaluated the efficacy and safety of the traditional Chinese medicine Jian Pi Qu Shi Formula (JPQSF) as a promising regimen. METHODS: We analyzed 15 consecutive patients with biopsy-proven idiopathic membranous nephropathy who failed immunosuppressive therapy from October 2013 to January 2017. JPQSF was administered orally two times per day, respectively, in the morning and at night for 6 months. All patients had at least 1 year of follow-up. The primary endpoints included complete or partial remission. Secondary endpoints included change of clinical parameters and adverse events after 12 months of treatment. RESULTS: After 12 months, complete remission was achieved in 13.3% of patients and partial remission in 66.7%, yielding a response rate of 80%. Proteinuria, serum albumin, and cholesterol were improved significantly (P<0.001, P<0.001, and P<0.05, respectively). After 1 year of treatment, proteinuria (mean ± SD) decreased from 5.93 ± 2.54 g per 24 h to 1.99 ± 1.17 g per 24 h (P<0.001). No serious adverse events occurred during the observation. CONCLUSIONS: JPQSF may be an alternative therapeutic option for steroid and general immunosuppressant-resistant membranous nephrotic syndrome patients, with a favorable safety profile. Larger and longer follow-up studies evaluating this regimen are warranted.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Evid Based Complement Alternat Med Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Evid Based Complement Alternat Med Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China